(by Nicola Simonetti) Biosimilar medicines are biotechnological medicines developed in such a way as to be extremely similar in quality, efficacy and safety to an already authorized biotechnological medicine ("originator or reference medicine"). The biosimilar has significantly lower costs without the efficacy and safety being lower than the originator. But doubts, reservations and refusals or consents have [...]
read more
Recent international studies and analyzes of pharmacovigilance data on biosimilars show results in line with the position taken and expressed by AIFA in its Second Position Paper. The scientific literature studies and the new evidence together with the use and pharmacovigilance data confirm the efficacy of biosimilar medicines and the interchangeability with respect to [...]
read more
“Biosimilar medicines are an important therapeutic resource and an opportunity to help ensure more and more the response to the emerging health need. In synergy with biological drugs, they can provide answers to the problem of undertreatment for numerous pathologies, guaranteeing access to therapies to an increasing number of patients "declared the General Manager [...]
read more